Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Kimberly Ward Part 3, Recruiting Healthcare Providers
HOMERUN SLIDES — Great Clinical Presentation Highlights
Beta-Cell Classification of Diabetes and the Egregious Eleven Part 3
CLINICAL GEMS — The Best from Diabetes Texts
MOST POPULAR ARTICLES OF THE MONTH
#1 How Will CGM’s Success Impact Conventional Glucose Monitors?
#2 Blood-Pressure Drug Could Be A Possible Type 1 Diabetes Cure
#3 Color Matters in Managing Hypertension
Editor's Note
We have all used the phrase “if you build it, they will come,” and when it comes to glucose monitoring systems and interconnectivity, it seems that every manufacturer has a belief that this is true. When Steve and Joy were at the recent ADA Scientific Sessions there were over 20 companies offering these systems, linking a monitor, the cloud, caregivers and providers to improve diabetes care.
The one failure point for every one of these systems is the time and effort that medical professionals have to take in order to use the information in their day to day practice. Our publisher, Steve Freed, sat down with Kimberly Ward from Roche Diabetes Care, to find out how they are making it easy for medical professionals to use their integrated system. Join us for part 3 of this interview to learn how this idea works.
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
When it comes to metformin, when appropriate, I recommend the extended release version. Last week my patient, female, 56 years of age, type 2 diabetes, visited. A1C was elevated, and she gained 5 pounds. She had been on metformin ER for the last 6 months and doing well. She said she recently noticed a bean-looking/pill-looking thing in her stools that seemed to be related to her metformin.
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
In part 3 of this Exclusive Interview, Kimberly Ward explains how to get busy healthcare providers to use the information provided by the Accu-Chek system.
HOMERUN SLIDES — Great Clinical Presentation Highlights
In this week’s Homerun Slides, debunking the myth that most patients with type 2 will eventually progress to insulin.
CLINICAL GEMS — The Best from Diabetes Texts
Autocrine effect of insulin on insulin secretion: Rodent and human pancreatic beta cells possess the various components of the insulin signaling system, including insulin receptor, insulin-like growth factor-1 (IGF-1) receptor, insulin receptor substrates (IRS-1 and IRS-2), phosphatidylinositol 3-kinase (PI3K), phosphoinositide-dependent kinase-1 (PDK1), and protein kinase B (PKB)/Akt. It has been shown that insulin binds to the insulin receptors on the surface of beta cells and induces phosphorylation of the insulin receptors and IRSs,modulating its own secretion. This effect of insulin is involved especially in the 1st phase of GIIS in mice.
MOST POPULAR ARTICLES OF THE MONTH
Guest Post by David Kliff, Diabetic Investor
The FDA approved Dexcom’s request for a non-adjunctive claim this week. It looks like a bad situation for conventional glucose monitors, and believe it or not is about to get worse. Here’s why.
A common blood pressure drug is showing new promise to help treat and cure type 1 diabetes.
African American male, 63 years of age, type 2 diabetes, hypertension, strong family history of type 2 diabetes, hypertension and stroke. A1C is 6.7%. Blood pressure 160/96 HR 88, despite being on ACE-I and Beta Blocker.